Three members of an independent panel that advised the U.S. FDA on nervous system drugs had resigned after the agency approved an Alzheimer's drug from Biogen.
Hector M. González, Associate Professor of Epidemiology and Biostatistics at Michigan State University, recently received a $5.67 million grant from the National Institute on Aging (NIA) to fuel a study to find very early signs of Alzheimer's disease among middle-age and older Latinos.
While the Latino older population is expected to triple by 2050, health experts are projecting that Latinos are disproportionately represented in the older age groups most at risk of Alzheimer's disease.
Alzheimer's & Dementia, a research journal, published a study which concluded that Mexican-Americans of a certain age commonly experience mild cognitive impairment (MCI), which is a memory hindrance. Mexican-Americans' risk for early Alzheimer's disease is ultimately due to the early onset of certain chronic health conditions.
